SCHEMBL4769216

SCHEMBL4769216

CCC1CN(C(=O)OC(C)(C)C)C(=O)CC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 2/20 0.37
CRBN Q96SW2 2/20 0.37
NR1H2 P55055 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
GLA P06280 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CYP2C19 P33261 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
KDM1A O60341 1/20 0.32
NAMPT P43490 1/20 0.32
BUB1 O43683 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23888477 0.87 DDB1 (0.36) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL30961345 0.87 NR1H2 (0.39) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL30625736 0.85 DDB1 (0.36) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL29701479 0.84 DDB1 (0.35) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL4774639 0.84 MME (0.38) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL15561535 0.83 DDB1 (0.37) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL30625814 0.83 DDB1 (0.39) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL29701789 0.83 BRD4 (0.43) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL23888537 0.83 DDB1 (0.34) DDB1CRBNNR1H2CHRM2CHRM1
SCHEMBL15561471 0.83 FAAH (0.46) DDB1CRBNNR1H2CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4480480-A2 SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF Bayer AG (DE) 2024-12-25 EP disclosed
EP-4188929-B1 SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF BAYER AG (DE) 2024-10-02 EP disclosed
WO-2024125451-A1 PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-20 WO disclosed
US-20230365554-A1 SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-16 US disclosed
EP-4188929-A1 SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2023-06-07 EP disclosed
US-20170133600-A1 ORGANIC LIGHT-EMITTING DIODE WITH HIGH EFFICIENCY AND LOW VOLTAGE SFC CO., LTD. (KR) 2017-05-11 US disclosed
EP-1660085-B1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-10-15 EP disclosed
EP-1660475-B1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-05-28 EP disclosed
US-7279575-B2 Pyrimidylpyrrole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2007-10-09 US disclosed
US-20070142414-A1 N-substituted pyrrolopyridinones active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2007-06-21 US disclosed
EP-1660085-A1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2006-05-31 EP disclosed
EP-1660475-A1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2006-05-31 EP disclosed
US-20050043323-A1 Pyrimidylpyrrole derivatives active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-02-24 US disclosed
US-20050043346-A1 Pyridylpyrrole derivatives active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-02-24 US disclosed
WO-2005014572-A1 PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2005-02-17 WO disclosed
WO-2005013986-A1 PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043346-A1 Pyridylpyrrole derivatives active as kinase inhibitors MAP3K6, MAP3K5, MAP4K2 DDB1 1516/4885CRBN 1229/4885NR1H2 4340/4885
US-20050043323-A1 Pyrimidylpyrrole derivatives active as kinase inhibitors TYMP, DTYMK, DCK DDB1 939/4885CRBN 2667/4885NR1H2 4606/4885
US-20170133600-A1 ORGANIC LIGHT-EMITTING DIODE WITH HIGH EFFICIENCY AND LOW VOLTAGE CYBA, ALDH1A2, AOC2 DDB1 2632/4885CRBN 2837/4885NR1H2 1244/4885
US-20230365554-A1 SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF PNPO, THPO, PLPBP DDB1 4333/4885CRBN 2879/4885NR1H2 2574/4885
US-20070142414-A1 N-substituted pyrrolopyridinones active as kinase inhibitors CDK2, MAP3K19, MAP3K7 DDB1 2672/4885CRBN 1159/4885NR1H2 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.